NVS logo

Novartis AG (NVS) Accounts Receivable

Annual Accounts Receivable

$7.42 B
+$316.00 M+4.45%

December 31, 2024

Summary

Performance

1-Year Change

+4.45%

3-Year Change

-7.27%

5-Year Change

-10.58%

15-Year Change

-13.69%

NVS Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.21%
NVS annual accounts receivable is higher than 98.21% of companies in Healthcare sector

High & Low

All-time High

$10.32 B
NVS annual accounts receivable is currently -28.09% below its historical high of $10.32 billion

3-Year Low

$7.11 B
NVS annual accounts receivable is currently +4.45% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NVS previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NVS next annual earnings announcement has not yet been scheduled

OtherNVSbalance sheetmetrics:

Annual Accounts Payable

$4.57 B
NVS annual accounts payable is $4.57 billion

Annual Total Assets

$102.25 B
NVS annual total assets is $102.25 billion

Annual Total Liabilities

$58.12 B
NVS annual total liabilities is $58.12 billion

Annual Cash & Cash Equivalents

$11.46 B
NVS annual cash & cash equivalents is $11.46 billion

Quarterly Accounts Receivable

$7.42 B
-$543.00 M-6.82%

December 31, 2024

Summary

Performance

3-Month Change

-6.82%

1-Year Change

+4.45%

3-Year Change

+8.86%

5-Year Change

+8.86%

NVS Quarterly Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.19%
NVS quarterly accounts receivable is higher than 98.19% of companies in Healthcare sector

High & Low

All-time High

$10.91 B
NVS quarterly accounts receivable is currently -31.99% below its historical high of $10.91 billion

3-Year Low

$6.82 B
NVS quarterly accounts receivable is currently +8.86% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Apr 23, 2025
NVS next earnings announcement is scheduled for Apr 23, 2025

OtherNVSbalance sheetmetrics:

Quarterly Accounts Payable

$4.57 B
NVS quarterly accounts payable is $4.57 billion

Quarterly Total Assets

$102.25 B
NVS quarterly total assets is $102.25 billion

Quarterly Total Liabilities

$58.12 B
NVS quarterly total liabilities is $58.12 billion

Quarterly Cash And Cash Equivalents

$11.46 B
NVS quarterly cash and cash equivalents is $11.46 billion

Accounts Receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

NVS Accounts Receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+4.5%+4.5%
3 y3 years-7.3%+8.9%
5 y5 years-10.6%+8.9%

NVS Accounts Receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-8.0%+4.5%-19.3%+8.9%
5 y5-year-10.6%+4.5%-19.3%+8.9%
alltimeall time-28.1%+130.0%-32.0%+130.0%

Novartis AG Accounts Receivable History

DateAnnualQuarterly
Dec 2024
$7.42 B(+4.4%)
$7.42 B(-6.8%)
Sep 2024
-
$7.97 B(-3.2%)
Jun 2024
-
$8.23 B(+4.9%)
Mar 2024
-
$7.84 B(+10.3%)
Dec 2023
$7.11 B(-11.9%)
$7.11 B(+4.2%)
Sep 2023
-
$6.82 B(-25.8%)
Jun 2023
-
$9.20 B(+3.1%)
Mar 2023
-
$8.92 B(+10.5%)
Dec 2022
$8.07 B(+0.8%)
$8.07 B(-4.2%)
Sep 2022
-
$8.42 B(-2.6%)
Jun 2022
-
$8.64 B(+2.8%)
Mar 2022
-
$8.41 B(+5.0%)
Dec 2021
$8.01 B(-2.6%)
$8.01 B(-4.4%)
Sep 2021
-
$8.38 B(-0.3%)
Jun 2021
-
$8.40 B(+1.6%)
Mar 2021
-
$8.27 B(+0.6%)
Dec 2020
$8.22 B(-1.0%)
$8.22 B(+1.8%)
Sep 2020
-
$8.07 B(+5.6%)
Jun 2020
-
$7.64 B(-10.5%)
Mar 2020
-
$8.54 B(+2.9%)
Dec 2019
$8.30 B(-4.9%)
$8.30 B(+6.1%)
Sep 2019
-
$7.83 B(-1.8%)
Jun 2019
-
$7.97 B(+4.7%)
Mar 2019
-
$7.61 B(-12.8%)
Dec 2018
$8.73 B(+1.5%)
$8.73 B(+1.7%)
Sep 2018
-
$8.59 B(-2.5%)
Jun 2018
-
$8.80 B(-1.3%)
Mar 2018
-
$8.92 B(+3.7%)
Dec 2017
$8.60 B(+4.9%)
$8.60 B(+1.4%)
Sep 2017
-
$8.48 B(+1.2%)
Jun 2017
-
$8.38 B(+1.8%)
Mar 2017
-
$8.23 B(+0.4%)
Dec 2016
$8.20 B(+0.3%)
$8.20 B(-4.0%)
Sep 2016
-
$8.55 B(-0.7%)
Jun 2016
-
$8.61 B(+1.7%)
Mar 2016
-
$8.46 B(+3.5%)
Dec 2015
$8.18 B(-1.1%)
$8.18 B(-3.7%)
Sep 2015
-
$8.49 B(-2.9%)
Jun 2015
-
$8.75 B(-0.5%)
Mar 2015
-
$8.79 B(+6.3%)
Dec 2014
$8.28 B(-16.4%)
$8.28 B(-6.6%)
Sep 2014
-
$8.86 B(-5.5%)
Jun 2014
-
$9.37 B(-9.2%)
Mar 2014
-
$10.32 B(+4.3%)
Dec 2013
$9.90 B(-1.5%)
$9.90 B(-5.7%)
Sep 2013
-
$10.50 B(-2.7%)
Jun 2013
-
$10.79 B(+2.9%)
Mar 2013
-
$10.48 B(+4.3%)
DateAnnualQuarterly
Dec 2012
$10.05 B(-2.6%)
$10.05 B(-4.4%)
Sep 2012
-
$10.52 B(+0.3%)
Jun 2012
-
$10.49 B(-1.1%)
Mar 2012
-
$10.61 B(+2.7%)
Dec 2011
$10.32 B(+4.6%)
$10.32 B(-3.6%)
Sep 2011
-
$10.70 B(-1.9%)
Jun 2011
-
$10.91 B(+0.5%)
Mar 2011
-
$10.86 B(+10.0%)
Dec 2010
$9.87 B(+18.8%)
$9.87 B(-5.0%)
Sep 2010
-
$10.39 B(+33.3%)
Jun 2010
-
$7.80 B(+0.3%)
Mar 2010
-
$7.77 B(-6.5%)
Dec 2009
$8.31 B(+18.3%)
$8.31 B(+6.3%)
Sep 2009
-
$7.82 B(+9.1%)
Jun 2009
-
$7.17 B(+6.2%)
Mar 2009
-
$6.75 B(-3.9%)
Dec 2008
$7.03 B(+5.7%)
$7.03 B(-3.1%)
Sep 2008
-
$7.25 B(+1.5%)
Jun 2008
-
$7.14 B(+3.8%)
Mar 2008
-
$6.88 B(+3.5%)
Dec 2007
$6.65 B(+7.9%)
$6.65 B(-2.4%)
Sep 2007
-
$6.81 B(+9.3%)
Jun 2007
-
$6.23 B(-1.9%)
Mar 2007
-
$6.35 B(+3.1%)
Dec 2006
$6.16 B(+15.3%)
$6.16 B(+1.2%)
Sep 2006
-
$6.09 B(+3.4%)
Jun 2006
-
$5.88 B(+11.2%)
Mar 2006
-
$5.29 B(-1.0%)
Dec 2005
$5.34 B(+10.1%)
$5.34 B(+4.0%)
Sep 2005
-
$5.14 B(+0.9%)
Jun 2005
-
$5.09 B(+4.8%)
Mar 2005
-
$4.86 B(+0.1%)
Dec 2004
$4.85 B(+10.9%)
$4.85 B(+8.0%)
Sep 2004
-
$4.49 B(+0.2%)
Jun 2004
-
$4.48 B(+3.6%)
Mar 2004
-
$4.33 B(-1.1%)
Dec 2003
$4.38 B(+18.4%)
$4.38 B(+2.9%)
Sep 2003
-
$4.25 B(-0.1%)
Jun 2003
-
$4.26 B(+8.4%)
Mar 2003
-
$3.93 B(+6.2%)
Dec 2002
$3.70 B(+14.5%)
$3.70 B(+0.9%)
Sep 2002
-
$3.66 B(+1.4%)
Jun 2002
-
$3.61 B(+11.9%)
Dec 2001
$3.23 B(-1.4%)
$3.23 B(-31.7%)
Jun 2001
-
$4.73 B(+44.4%)
Dec 2000
$3.27 B(-26.0%)
$3.27 B
Dec 1999
$4.42 B(+4.6%)
-
Dec 1998
$4.23 B
-

FAQ

  • What is Novartis AG annual accounts receivable?
  • What is the all time high annual accounts receivable for Novartis AG?
  • What is Novartis AG annual accounts receivable year-on-year change?
  • What is Novartis AG quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Novartis AG?
  • What is Novartis AG quarterly accounts receivable year-on-year change?

What is Novartis AG annual accounts receivable?

The current annual accounts receivable of NVS is $7.42 B

What is the all time high annual accounts receivable for Novartis AG?

Novartis AG all-time high annual accounts receivable is $10.32 B

What is Novartis AG annual accounts receivable year-on-year change?

Over the past year, NVS annual accounts receivable has changed by +$316.00 M (+4.45%)

What is Novartis AG quarterly accounts receivable?

The current quarterly accounts receivable of NVS is $7.42 B

What is the all time high quarterly accounts receivable for Novartis AG?

Novartis AG all-time high quarterly accounts receivable is $10.91 B

What is Novartis AG quarterly accounts receivable year-on-year change?

Over the past year, NVS quarterly accounts receivable has changed by +$316.00 M (+4.45%)